in these cells, compared with the control serum. Since BMP-2 induces ectopic bone and cartilage formation in extraskeletal tissues in vivo and activates AVCR1, the present data suggest the possibility that there might be some serum soluble factors, which enhancing muscle ossification in the FOP patient.

Bone resorption and bone formation indices are increased and decreased in this FOP patient. The use of glucocorticoid and long-term immobilization might enhance bone resorption. The direct action of glucocorticoid on the gene expression in skeletal cells plays the main role in glucocorticoid-induced osteoporosis (GIO). In GIO, glucocorticoid induces a decrease in osteoblastgenesis and an increase in the apoptosis of mature osteoblast and osteocyte, by inhibiting the expression of osteoblastic key genes, resulting in osteoblastic bone formation [12].

Immobilization induces bone loss, since the reduction of compressive mechanical forces during immobilization results in stimulating osteoclast activity by inducing bone resorption factors, such as receptor activator of NF-κB ligand [13]. In this patient, the long-term immobilization state might enhance bone resorption, leading to an increase of bone resorption indices in spite of glucocorticoid administration. The change of some soluble factors in the serum of this patient by glucocorticoid use and immobilization might be responsible for enhancing the level of ALP, OCN and BMP-2 in osteoblast. Furthermore, increased bone resorption indices may be due to BMP-2, stimulation of bone resorption by enhanced osteoclast formation, and osteoclastic activity [14,15]. Okamoto et al. [16] reported that mice overexpressing BMP- 4 in bone developed severe osteopenia with increased osteoclast number. Enhanced BMP activity itself might be one of the causes of enhanced bone resorption indices in this FOP patient.

The serum was obtained before taking 0.75 mg betamethazone in the morning, 24 hr after administration the previous day. Serum concentration of betamethasone, the next morning, was considered to be very low, since Miyachi et al. reported that betamethazone in the serum disappeared 24 hr after oral administration, otherwise the patient developed liver failure [17]. These findings indicate that the residual betamethasone did not modulate the effects of serum from the FOP patient in the present study.

5. Conclusion

We presented a case of FOP with progressive ossification in extra-skeletal tissues with ACVR1 mutation. This mutation was responsible for the pathogenesis in this patient. From the present data, a systemic humoral factor may be related to the pathogenesis of FOP in this patient. Some bone anabolic factors might be elevated in the serum from the patient with FOP. Alternatively, some inhibitory factors for bone formation could be suppressed in the patient serum. Moreover, the effects of the patient serum on ALP, OCN and BMP-2 should be confirmed in several patients with FOP. Further studies are necessary to clarify this issue and will be performed in the near future.

6. Acknowledgements

We greatly thank Yoshiko Higashimaki and Erika Matsumoto for expert technical assistance. This work was supported in part by a grant from a grant-in-aid (21591179) from the Ministry of Science, Education, and Culture of Japan (to H.K), the Global COE Program F11 from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

REFERENCES

  1. J. M. Connor and D. A. Evans, “Fibrodysplasia Ossificans Progressiva: The Clinical Features and Natural History of 34 Patients,” Journal of Bone and Joint Surgery of Britain, Vol. 64, No. 1, 1982, pp. 76-83.
  2. G. Feldman, M. Li, S. Martin, M. Urbanek, J. A. Urtizberea, M. Fardeau, M. LeMerrer, J. M. Connor, J. M. Triffitt, R. Smith, M. Muenke, F. S. Kaplan and E. M. Shore, “Fibrodysplasia Ossificans Progressiva, a Heritable Disorder of Severe Heterotopic Ossification, Maps to Human Chromosome 4q27-31,” American Journal of Human Genetics, Vol. 66, 2000, pp. 128-135. doi:10.1086/302724
  3. F. H. Gannon, B. A. Valentine, E. M. Shore, M. A. Zasloff and F. S. Kaplan, “Acute Lymphocytic Infiltration in an Extremely Early Lesion of Fibrodysplasia Ossificans Progressiva,” Clinical and Orthopedic Related Research, Vol. 346, 1998, pp. 19-25. doi:10.1097/00003086-199801000-00005
  4. A. B. Shafritz, E. M. Shore, F. H. Gannon, M. A. Zasloff, R. Taub, M. Muenke and F. S. Kaplan, “Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva,” New England Journal of Medicine, Vol. 22, 1996, pp. 555-561. doi:10.1056/NEJM199608223350804
  5. E. A. Olmsted, F. S. Kaplan and E. M. Shore, “Bone Morphogenic Protein-4 Regulation in Fibrodysplasia Ossificans Progressiva,” Clinical and Orthopedic Related Research, Vol. 408, 2003, pp. 331-343. doi:10.1097/00003086-200303000-00044
  6. L. S. de la Pena, P. C. Billings, J. L. Fiori, J. Ahn, F. S. Kaplan and E. M. Shore, “Fibrodisplasia Ossificans Progressiva (FOP), a Disorder of Ectopic Osteogenesis, MisRegulates Cell Surface Expression and Trafficking BMPRIA,” Journal of Bone and Mineral Research, Vol. 20, No. 7, 2005, pp. 1168-1176. doi:10.1359/JBMR.050305
  7. E. M. Shore, M. Xu, G. J. Feldman, D. A. Fenstermacher, T. J. Cho, I. H. Choi, J. M. Connor, P. Delai, D. L. Glaser, M. LeMerrer, R. Morhart, J. G. Rogers, S. Roger, J. T. Triffitt, J. A. Urtizberea, M. Zasloff, M. A. Brown and F. S. Kaplan, “A Recurrent Mutation in the BMP Type I Receptor ACVR1 Causes Inherited and Sporadic Fibrodysplasia Ossificans Progressiva,” Nature Genetics, Vol. 38, 2006, pp. 525-527. doi:10.1038/ng1783
  8. G. Li, H. Peng, K. Corsi, A. Usas, A. Olshanski and J. Huard, “Differential Effect of BMP4 on NIH/3T3 and C2C12 Cells: Implications for Endochondral Bone Formation,” Journal of Bone and Mineral Research, Vol. 20, No. 9, 2005, pp. 1611-1623. doi:10.1359/JBMR.050513
  9. I. Hisa, Y. Inoue, G. N. Hendy, L. Canaff, R. Kitazawa, S. Kitazawa, T. Komori, T. Sugimoto, S. Seino and H. Kaji, “Parathyroid Hormone-Responsive Smad3-Related Factor, Tmem119, Promotes Osteoblast Differentiation and Interacts with the Bone Morphogenetic Protein-Runx2 Pathway,” Journal of Biological Chemistry, Vol. 286, 2011, pp. 9787-9796. doi:10.1074/jbc.M110.179127
  10. J. M. Wozney, V. Rosen, A. J. Celeste, L. M. Mitsock, M. J. Whitters, R. W. Kriz, R. M. Hewick and E. A. Wang, “Novel Regulators of Bone Formation: Molecular Clones and Activities,” Science, Vol. 242, No. 4885, 1988, pp. 1528-1534. doi:10.1126/science.3201241
  11. E. Canalis, A. N. Economides and E. Gazzerro, “Bone Morphogenetic Proteins, Their Antagonists, and the Skelton,” Endocrine Reviews, Vol. 24, No. 2 2003, pp. 218-235. doi:10.1210/er.2002-0023
  12. S. Epstein, A. M. Inzerillo, J. Caminis and M. Zaidi, “Disorders Associated with Acute Rapid and Severe Bone Loss,” Journal of Bone and Mineral Research, Vol. 18, No. 12, 2003, pp. 2083-2094. doi:10.1359/jbmr.2003.18.12.2083
  13. E. Canalis and A. Giustina, “Glucocorticoid-Induced Osteoporosis: Summary of a Workshop,” Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 12, 2001, pp. 5681-5685. doi:10.1210/jc.86.12.5681
  14. M. Kanatani, T. Sugimoto, H. Kaji, T. Kobayashi, K. Nishiyama, M. Fukase, M. Kumegawa and K. Chihara, “Stimulatory Effect of Bone Morphogenetic Protein-2 on Osteoclast-Like Cell Formation and Bone Resorbing Activity,” Journal of Bone and Mineral Research, Vol. 10, No. 11, 1995, pp. 1681-1690. doi:10.1002/jbmr.5650101110
  15. H. Kaneko, T. Arakawa, H. Mano, T. Kaneda, A. Ogasawara, M. Nakagawa, Y. Toyama, Y. Yabe, M. Kumegawa and Y. Hakeda, “Direct Stimulation of Osteoclastic Bone Resorption by Bone Morphognetic Protein (BMP)-2 and Expression of BMP Receptors in Mature Osteoclasts,” Bone, Vol. 27, No. 24, 2000, pp. 479-486. doi:10.1016/S8756-3282(00)00358-6
  16. M. Okamoto, J. Murai, H. Yoshikawa and N. Tsumaki, “Bone Morphogenetic Proteins in Bone Stimulate Osteoclasts and Osteoblasts during Bone Development,” Journal of Bone and Mineral Research, Vol. 21, No. 7, 2006, pp. 1022-1033. doi:10.1359/jbmr.060411
  17. Y. Miyachi, H. Yotsumoto, T. Kano, A. Mizuchi, T. Muto and L. Yanagibashi, “Blood Levels of Synthetic Glucocorticoids After Administration by Various Routes,” Journal of Endocrinology, Vol. 82, 1978, pp. 149-157. doi:10.1677/joe.0.0820149

NOTES

*Corresponding author.

Journal Menu >>